All In Biotech

Drug Trial Radar · NCT00406887

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis

Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis).

Last checked: Nov 20, 2026Latest source record: Dec 4, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Aug 2002

Primary completion

Not stated

Study completion Nov 2003

Sponsor

Lead sponsor
Sirion Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase 3 confirmatory study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of treatment of uveitis.

Conditions

  • Anterior Uveitis
  • Panuveitis

Interventions

  • Difluprednate Ophthalmic EmulsionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The difference from the baseline in anterior chamber cell score on Day 14
  2. was compared between the two groups.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.